<DOC>
	<DOCNO>NCT01495793</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalation , Phase 2A study multiple administration rotigotine transdermal system . The study conduct adolescent subject ( 13 &lt; 18 year age ) idiopathic Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>Dose Escalating Study Rotigotine Pediatric Subjects With Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject parent/legal representative consider reliable capable adhere protocol Subject male female , ≥13 &lt; 18 year age Visit 2/Baseline Subject weighs ≥40 kg Visit 2/Baseline Subject 's Body Mass Index ( BMI ) less 95th percentile age Visit 2/Baseline Subject meet diagnosis RLS base proposed 2011 Revised International Restless Legs Syndrome Study Group Diagnostic Criteria Subject 's RLS symptom cause significant distress impairment At Visit 2/Baseline , subject Periodic Limb Movement Index ( PLMI ) ≥5 least 1 5 night prior Baseline measure activity monitor At Visit 2/Baseline , subject score ≥15 IRLS Rating Scale At Visit 2/Baseline , subject score ≥4 point Clinical Global Impression ( CGI ) Item 1 assessment Subject receive supplemental iron stable dose least 3 month prior Visit 1/Screening Period Previously participate study receive previous treatment rotigotine Participated another study investigational medicinal product ( IMP ) medical device within last 3 month prior Visit 1/Screening Period currently participate another study IMP medical device Subject 's RLS symptom restrict ankle knee RLS symptom due renal insufficiency ( uremia ) iron deficiency anemia Previous treatment dopamine agonist within period 14 day prior Visit 2/Baseline Ldopa within 7 day prior Visit 2/Baseline Failed respond previous dopaminergic therapy Any medical psychiatric condition , opinion investigator , would jeopardize compromise subject 's well ability participate Subject lifetime history suicide attempt suicidal ideation past 6 month Evidence impulse control disorder ( ICD ) History current symptom sleep apnea , narcolepsy , sleep attacks/sudden onset sleep , myoclonus epilepsy Concomitant diseases peripheral neuropathy , muscle fasciculation , painful leg move toe , fibromyalgia , rheumatoid arthritis , sickle cell disease Serum ferritin level &lt; 15 ng/mL Subject attempt least 1 nonpharmacological intervention management RLS ( eg , sleep hygiene , exercise ) Prior history psychotic episode History chronic alcohol drug abuse within 12 month prior Screening Period Clinically relevant cardiac dysfunction and/or arrhythmias Hemoglobin level lower limit normal Clinically relevant renal dysfunction ( serum creatinine &gt; 1.5 mg/dL ) Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin level great equal 2 time upper limit normal History presence clinical sign malignant neoplasm include suspicious undiagnosed skin lesion ( may melanoma ) , melanoma , history melanoma Currently receive receive treatment follow within 28 day prior Visit 2/Baseline : neuroleptic , antidepressant , anxiolytic drug , opioids , monoamine oxidase ( MAO ) inhibitor , sedative antihistamine Currently receive treatment follow : benzodiazepine , hypnotic , anticonvulsant , central alphaadrenergic agonist , melatonin ; unless treatment RLS , case WashOut Period least 14 day prior Visit 2/Baseline require Currently receive stimulant therapy attention deficit hyperactivity disorder ( ADHD ) ; WashOut Period least 7 day prior Visit 2/Baseline require Pregnant , nursing , woman childbearing potential surgically sterile , consistently use 2 combine medically acceptable method contraception ( include least 1 barrier method ) , unless sexually active Unwilling abstain caffeine 4pm evening within 7 day prior Visit 2/Baseline duration study Pursues shift work performs continuous nondiseaserelated life condition , allow regular sleep night Subject QT correction ( QTc ) interval ≥500 ms Visit 1/Screening Period Visit 2/Baseline . Bazett 's correction method must use correction QT interval Symptomatic orthostatic hypotension decrease blood pressure ( BP ) supine stand position ≥20 mmHg systolic blood pressure ( SBP ) ≥10 mmHg diastolic blood pressure ( DBP ) take 5 minute supine 1 and/or 3 minute standing measurement A know hypersensitivity component study medication , history significant skin hypersensitivity adhesive , know hypersensitive</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
</DOC>